Literature DB >> 30990918

Sarcopenic obesity predicts nonremission of late-life depression.

Kitty J E Kokkeler1,2, Karen S van den Berg2,3, Hannie C Comijs4, Richard C Oude Voshaar2, Radboud M Marijnissen1,2.   

Abstract

BACKGROUND/
OBJECTIVES: Aging-related physiological changes like metabolic dysregulation and physical frailty are associated with depression and worsen its prognosis. Since central obesity is a key component of the metabolic syndrome and sarcopenia of physical frailty, we examined the association of sarcopenic obesity with depression cross-sectional and over time.
METHODS: Cohort study of depressed patients and a nondepressed comparison group.
SETTING: Primary and secondary mental health care. PARTICIPANTS: Three hundred seventy-eight older (≥60 y) depressed patients of which 285 were followed up at 2 years and 132 nondepressed persons participating in the Netherlands Study of Depression in Older (NESDO) persons. MEASUREMENTS: Sarcopenic obesity was based on predefined cutoffs for both maximum handgrip strength (assessed with a dynamometer) and waist circumference (dichotomous) as well as the product term of handgrip strength by waist circumference (dimensional). Depressive disorder according to DSM-IV-TR criteria was assessed with fully structured psychiatric interview at baseline and 2-year follow-up.
RESULTS: Sarcopenic obesity was more prevalent among depressed patients compared with nondepressed participants (18.9% versus 10.7%, P = 0.030). Neither the dichotomous nor dimensional operationalization of sarcopenic obesity was associated with baseline depressive disorder when adjusted for covariates. Nonetheless, among depressed patients, logistic regression showed that the interaction of handgrip strength by waist circumference was associated with remitted depression at 2-year follow-up (P = 0.044). Only among patients with a low handgrip strength, a higher waist circumference predicted nonremission.
CONCLUSION: Among depressed patients, sarcopenic obesity predicts nonremission of depression. Therefore, combined exercise and nutritional interventions might be effective for depressed patients with sarcopenic obesity.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  abdominal obesity; depression; elderly; sarcopenia; sarcopenic obesity

Mesh:

Year:  2019        PMID: 30990918     DOI: 10.1002/gps.5121

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  6 in total

1.  Prevalence and Determinants of Sarcopenic Obesity in Older Adults: Secondary Data Analysis of the Longitudinal Ageing Study in India (LASI) Wave 1 Survey (2017-18).

Authors:  Madhur Verma; Nitin Kapoor; Aditi Chaudhary; Priyanka Sharma; Nilanjana Ghosh; Shivani Sidana; Rakesh Kakkar; Sanjay Kalra
Journal:  Adv Ther       Date:  2022-07-05       Impact factor: 4.070

2.  Early-onset late-life depression: Association with body mass index, obesity, and treatment response.

Authors:  Woo Ri Chae; Manuel Fuentes-Casañ; Felix Gutknecht; Angela Ljubez; Stefan M Gold; Katja Wingenfeld; Christian Otte
Journal:  Compr Psychoneuroendocrinol       Date:  2021-10-23

3.  Handgrip Strength and Depression Among Older Chinese Inpatients: A Cross-Sectional Study.

Authors:  Xiao-Ming Zhang; Jing Jiao; Jing Cao; Na Guo; Chen Zhu; Zhen Li; Xinjuan Wu; Tao Xu
Journal:  Neuropsychiatr Dis Treat       Date:  2021-04-30       Impact factor: 2.570

4.  Using Dietary Macronutrient Patterns to Predict Sarcopenic Obesity in Older Adults: A Representative Korean Nationwide Population-Based Study.

Authors:  Jun-Hyuk Lee; Hye-Min Park; Yong-Jae Lee
Journal:  Nutrients       Date:  2021-11-11       Impact factor: 5.717

5.  Association among calf circumference, physical performance, and depression in the elderly Chinese population: a cross-sectional study.

Authors:  Jian-Yu Tan; Qing-Lian Zeng; Meng Ni; Ying-Xiao Zhang; Tian Qiu
Journal:  BMC Psychiatry       Date:  2022-04-20       Impact factor: 4.144

6.  The Prevalence of Sarcopenia in Bipolar Disorder.

Authors:  Feridun Bulbul; Irfan Koca; Lut Tamam; Mehmet Emin Demirkol; Soner Cakmak; Emre Ersahinoglu
Journal:  Neuropsychiatr Dis Treat       Date:  2020-04-08       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.